Skip to main content

Advertisement

SpringerLink
Log in

Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Functionally critically located gliomas represent a challenging subgroup of intrinsic brain neoplasms. Standard therapeutic recommendations often cannot be applied, because radical treatment and preservation of neurological function are contrary goals. The successful targeting of gliomas with locally injected beta radiation-emitting 90Y-DOTAGA-substance P has been shown previously. However, in critically located tumours, the mean tissue range of 5 mm of 90Y may seriously damage adjacent brain areas. In contrast, the alpha radiation-emitting radionuclide 213Bi with a mean tissue range of 81 µm may have a more favourable toxicity profile. Therefore, we evaluated locally injected 213Bi-DOTA-substance P in patients with critically located gliomas as the primary therapeutic modality.

Methods

In a pilot study, we included five patients with critically located gliomas (WHO grades II–IV). After diagnosis by biopsy, 213Bi-DOTA-substance P was locally injected, followed by serial SPECT/CT and MR imaging and blood sampling. Besides feasibility and toxicity, the functional outcome was evaluated.

Results

Targeted radiopeptide therapy using 213Bi-DOTA-substance P was feasible and tolerated without additional neurological deficit. No local or systemic toxicity was observed. 213Bi-DOTA-substance P showed high retention at the target site. MR imaging was suggestive of radiation-induced necrosis and demarcation of the tumours, which was validated by subsequent resection.

Conclusion

This study provides proof of concept that targeted local radiotherapy using 213Bi-DOTA-substance P is feasible and may represent an innovative and effective treatment for critically located gliomas. Primarily non-operable gliomas may become resectable with this treatment, thereby possibly improving the prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Lacroix M, Abi-Said D, Fourney DR, Gikaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95(2):190–8.

    Article  CAS  PubMed  Google Scholar 

  2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987–96.

    Article  CAS  PubMed  Google Scholar 

  3. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 2008;62(3):564–76. discussion 564–576.

    Article  PubMed  Google Scholar 

  4. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753–64. discussion 264–756.

    Article  PubMed  Google Scholar 

  5. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7(5):392–401.

    Article  CAS  PubMed  Google Scholar 

  6. Fahlbusch R, Nimsky C. Intraoperative MRI developments. Neurosurg Clin N Am 2005;16(1):xi–xiii.

    Article  PubMed  Google Scholar 

  7. Nimsky C, Ganslandt O, Fahlbusch R. Functional neuronavigation and intraoperative MRI. Adv Tech Stand Neurosurg 2004;29:229–63.

    CAS  PubMed  Google Scholar 

  8. Kaloshi G, Benouaich-Amiel A, Diakite F, Tallibert S, Lejeune J, Laigle-Donadey F, et al. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007;68(21):1831–6.

    Article  CAS  PubMed  Google Scholar 

  9. van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985–90.

    Article  PubMed  Google Scholar 

  10. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002;20(8):2076–84.

    Article  PubMed  Google Scholar 

  11. Stieber VW. Low-grade gliomas. Curr Treat Options Oncol 2001;2(6):495–506.

    Article  CAS  PubMed  Google Scholar 

  12. Hoang-Xuan K, Capelle L, Kujas M, Tallibert S, Duffau H, Lejeune J, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133–8.

    Article  CAS  PubMed  Google Scholar 

  13. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30(9):907–11.

    CAS  PubMed  Google Scholar 

  14. Hennig IM, Laissue JA, Horisberger U, Reubi JC. Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 1995;61(6):786–92.

    Article  CAS  PubMed  Google Scholar 

  15. Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res 2006;12(12):3843–50.

    Article  CAS  PubMed  Google Scholar 

  16. Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J Nucl Med 2006;47(6):1007–15.

    CAS  PubMed  Google Scholar 

  17. Raja C, Graham P, Abbas Rizvi SM, Song E, Goldsmith H, Thompson J, et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2007;6(6):846–52.

    Article  CAS  PubMed  Google Scholar 

  18. Allen BJ, Raja C, Rizvi S, Tsui W, Graham P, Thompson JF, et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2005;4(12):1318–24.

    Article  CAS  PubMed  Google Scholar 

  19. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002;100(4):1233–9.

    CAS  PubMed  Google Scholar 

  20. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem 2005;77(19):6288–91.

    Article  CAS  PubMed  Google Scholar 

  21. Apostolidis C, Molinet R, McGinley J, Abbas K, Mollenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot 2005;62(3):383–7.

    Article  CAS  PubMed  Google Scholar 

  22. Sangha H, Lipson D, Foley N, Salter K, Bhogal S, Pohani G, et al. A comparison of the Barthel Index and the Functional Independence Measure as outcome measures in stroke rehabilitation: patterns of disability scale usage in clinical trials. Int J Rehabil Res 2005;28(2):135–9.

    Article  PubMed  Google Scholar 

  23. Zielinska B, Apostolidis C, Bruchertseifer F, Morgenstern A. An improved method for the production of Ac-225/Bi-213 from Th-229 for targeted alpha therapy. Solv Extr Ion Exch 2007;25(3):339–49.

    Article  CAS  Google Scholar 

  24. Bruchertseifer FGS, Apostolidis C, Mäcke H, Morgenstern A. An improved method for Bi-213 labelling of DOTA-/DOTAGA-chelated peptides. Eur J Nucl Med Mol Imaging 2006;33(S2):S161.

    Google Scholar 

  25. Merlo A, Hausmann O, Wasner M, Steiner P, Otte A, Jermann E, et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 1999;5(5):1025–33.

    CAS  PubMed  Google Scholar 

  26. Merlo A, Jermann E, Hausmann O, Chiquet-Ehrismann R, Probst A, Landolt H, et al. Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas. Int J Cancer 1997;71(5):810–6.

    Article  CAS  PubMed  Google Scholar 

  27. Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging 2002;29(4):486–93.

    Article  CAS  PubMed  Google Scholar 

  28. Nimsky C, von Keller B, Schlaffer S, Kuhnt D, Weigel D, Ganslandt O, et al. Updating navigation with intraoperative image data. Top Magn Reson Imaging 2009;19(4):197–204.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the European Commission FP7, contract TARCC No.HEALTH-F2-2007-201962.

Author information

Authors and Affiliations

  1. Division of Neurosurgery, University Hospitals, Basel, Switzerland

    D. Cordier & A. Merlo

  2. Institute of Nuclear Medicine, University Hospitals, Basel, Switzerland

    F. Forrer, S. Good, J. Müller-Brand & H. Mäcke

  3. European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany

    F. Bruchertseifer, A. Morgenstern & C. Apostolidis

  4. Nuclear Medicine and Radiological Chemistry, University Hospital Basel, Basel, Switzerland

    H. Mäcke

  5. Institute of Pathology, University of Berne, Berne, Switzerland

    J. C. Reubi

Authors
  1. D. Cordier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Forrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Bruchertseifer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Morgenstern
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Apostolidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Good
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Müller-Brand
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H. Mäcke
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. C. Reubi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Merlo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Cordier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cordier, D., Forrer, F., Bruchertseifer, F. et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging 37, 1335–1344 (2010). https://doi.org/10.1007/s00259-010-1385-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-010-1385-5

Keywords

Search

Navigation